Content uploaded by Bill Elliot Cham
Author content
All content in this area was uploaded by Bill Elliot Cham on Apr 12, 2016
Content may be subject to copyright.
A preview of the PDF is not available
The Eggplant Cancer Cure: A Treatment for Skin Cancers and New Hope from Nature's Pharmacy
... Induction of apoptosis in cancer cells or malignant tissues is accepted as an efficient approach for cancer chemotherapy. Figure 3 shows that BEC rapidly kills cancer cells by the characteristic apoptotic pathway of cell shrinkage, condensation of chromatin and nuclear fragmentation [32,38]. ...
... Subsequently clinical trials using 10% of BEC in a cream formulation determined that this formulation was effective for the treatments of keratoses, BCCs and SCCs [46]. More recently clinical trials with Curaderm BEC5 containing 0.005% BEC showed impressive results when, even very large nonmelanoma skin cancers were treated [2,27,34,38,[41][42][43][44][54][55][56]. BEC present in Curaderm BEC5 is at a much lower concentration than is found naturally in the eggplant [10]. ...
... However, the eggplant also contains anticancer inhibitors which must be removed in order to obtain the anticancer benefits shown with Curaderm BEC5 therapy. Accordingly, and as shown by many studies, BEC in Curaderm BEC5 is very safe [2,9,27,34,38,[41][42][43][44][54][55][56]. ...
Skin cancer incidence is increasing at alarming rates and is considered by some as an epidemic. Its incidence is higher than all other cancers combined. The developments of new treatments have not parallelled the increased incidences of this disease. A variety of treatments are available with differing outcomes. More recently a novel topical treatment, consisting of the antineoplastic compounds solasodine rhamnosyl glycosides, solamargine and solasonine, which are derived from plant material, has been described that claims to have many advantages over the currently used skin can-cer therapies. This review investigates such claims.
... Curaderm BEC5 is a topical cream which contains a mixture of solasodine glycosides (BEC) and is very effective for treating nonmelanoma skin cancers. Advantages of treatment of these lesions with Curaderm BEC5 compared with well established surgical interventions and other therapies have previously been reported [1][2][3]19,20,24,28,29,[33][34][35][36][37]. ...
... The treatment time period with topical Curaderm BEC5 to completely eliminate skin cancers varies from days to months depending on size and type of skin tumours. Large nonmelanoma skin cancers can successfully be treated with Curaderm BEC5 and it may take several months of treatment to eliminate these large tumours [1][2][3]19,20,24,28,29,33,[33][34][35][36][37]. ...
... Limitations and costs of current treatments for skin cancers pose many shortfalls and many patients afflicted with these diseases do not seek proper treatment, resulting in increased morbidity and mortality [1,3,40,41]. ...
Solasodine rhamnosyl glycosides (SRGs) are chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation, CuradermBEC5, is very effective for the treatment of nonmelanoma skin cancers with excellent cosmetic end results. Intralesion injection of SRGs successfully dispose of very large tumours in animals without any clinical adverse effects. The mode of action of SRGs is by apoptosis. In this study, it is shown that small to large basal cell car-cinomas are effectively treated only with topical application of CuradermBEC5. Here it is reported for the first time that combination of intralesion SRG injection and topical application with CuradermBEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime. Two intralesion injections of very low doses of SRGs rapidly and effectively remove a large melanoma on a horse. If rapid removal of large troublesome skin cancers is required then this can be achieved by intralesion and topical treatments. Intralesion or combination therapy with SRGs may have some applications for melanomas in situ such as lentigo maligna.
... Curaderm BEC5 is a topical cream which contains a mixture of solasodine glycosides (BEC) and is very effective for treating nonmelanoma skin cancers. Advantages of treatment of these lesions with Curaderm BEC5 compared with well established surgical interventions and other therapies have previously been reported [1][2][3]19,20,24,28,29,[33][34][35][36][37]. ...
... The treatment time period with topical Curaderm BEC5 to completely eliminate skin cancers varies from days to months depending on size and type of skin tumours. Large nonmelanoma skin cancers can successfully be treated with Curaderm BEC5 and it may take several months of treatment to eliminate these large tumours [1][2][3]19,20,24,28,29,33,[33][34][35][36][37]. ...
... Limitations and costs of current treatments for skin cancers pose many shortfalls and many patients afflicted with these diseases do not seek proper treatment, resulting in increased morbidity and mortality [1,3,40,41]. ...
Solasodine rhamnosyl glycosides (SRGs) are chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation, Curaderm BEC5 , is very effective for the treatment of nonmelanoma skin cancers with excellent cosmetic end results. Intralesion injection of SRGs successfully dispose of very large tumours in animals without any clinical adverse effects. The mode of action of SRGs is by apoptosis. In this study, it is shown that small to large basal cell carcinomas are effectively treated only with topical application of Curaderm BEC5 . Here it is reported for the first time that combination of intralesion SRG injection and topical application with Curaderm BEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime. Two intralesion injections of very low doses of SRGs rapidly and effectively remove a large melanoma on a horse. If rapid removal of large troublesome skin cancers is required then this can be achieved by intralesion and topical treatments. Intralesion or combination therapy with SRGs may have some applications for melanomas in situ such as lentigo maligna.
... BEC is a mixture of solasodine glycosides consisting of the triglycosides solasonine (β-solatriose) (33%), solamargine (β-chacotriose) (33%), and di-and-monoglycosides (34%). All the glycosides contain the same aglycone solasodine [19][20][21][22][23][24]. ...
... BEC enhances the intrinsic ratio of Bax to Bcl-2 by upregulating Bax and down-regulating Bcl-2 and Bcl-x expressions. These effects result in activation of Caspase-8, -9 and -3 in cancer cells [24][25][26][27][28][29][30][31][32][33][34], indicating that BEC triggers extrinsic and intrinsic apoptotic pathways in cancer cells and causes apoptosis to cancer cells. ...
Approximately 5 to 10 percent of all skin cancers occur in the periocular region. Basal cell carcinoma is the most fre- quent malignant periocular tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Nonmelanoma skin tumors at the periocular area often cause disfigurement with destruction of soft conjunc- tival tissue. Many therapeutic methods have been recommended to combat the morbidity and mortality associated with these lesions. Excisions with frozen-section control or Mohs micrographic surgery are regarded as the gold-standard treatments for periocular basal cell and squamous cell carcinomas. However, these treatment modalities have various limitations and reconstruction surgery is often associated with these treatment options. The chemotherapeutic agents solasodine rhamnosides in a cream formulation CuradermBEC5 are specific, effective and safe treatments for nonmela- noma skin cancers with excellent cosmesis. The antineoplastic mode of action is by apoptosis. In this review it is shown that CuradermBEC5 also treats periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no reconstructive surgery is required.
http://www.appleacademicpress.com/nutraceuticals-and-dietary-supplements-applications-in-health-improvemepnt-and-disease-management-/9781771888738
https://www.taylorfrancis.com/books/e/9780367821517
ResearchGate has not been able to resolve any references for this publication.